Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy

APLS -1.34%

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now. On November 12, Apellis Pharmaceuticals announced that a post hoc analysis of the Phase 3 GALE extension study showed the long-term benefit of SYFOVRE (pegcetacoplan injection) for geographic atrophy/GA secondary to age-related macular degeneration/AMD.

Following 5 years of continuous treatment, the data showed that both monthly and every-other-month administration of SYFOVRE delayed GA lesion growth by ~1.5 years in patients with non-subfoveal GA when compared to sham/projected sham. This is significant because GA is a progressive and irreversible disease caused by growing lesions that destroy retinal cells and is a leading cause of blindness worldwide, impacting over 1 million Americans and 5 million people globally.

SYFOVRE (pegcetacoplan injection) is the first-ever FDA-approved therapy for geographic atrophy, working by targeting C3 to provide comprehensive control of the complement cascade. It is indicated for the treatment of GA secondary to age-related macular degeneration in the US. SYFOVRE is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, and those with hypersensitivity to pegcetacoplan.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds to treat diseases with high unmet needs.

While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.